巻号一覧
前身誌
62 巻, 6 号
選択された号の論文の6件中1～6を表示しています
- |<
- <
- 1
- >
- >|
-
第1報-乾燥濾紙血液17α-hydroxyprogesteroneの酵素免疫測定法の基礎的検討と新生児マス・スクリーニングへの応用-福士 勝, 荒井 修, 水嶋 好清, 高杉 信男, 藤枝 憲二, 松浦 信夫1986 年 62 巻 6 号 p. 683-696
発行日: 1986/06/20
公開日: 2012/09/24
ジャーナル フリーAn enzyme immunoassay for measuring 17α-hydroxyprogesterone (17-OHP) in dried blood collected on filter paper has been developed. The method is easy and rapid and has specificity, accuracy and precision.
17-OHP values of neonates with congenital adrenal hyperplasia (CAH, 40ng/ml) were extremely high compared with normal neonates (1.1± 0.7ng/ml). There was a negative correlation between the 17-0HP value and birth weight.
The method has been applied to neonatal screening for CAH due to 21-hydroxylase deficiency. During 38 months, 67,392 neonates were screened. The recall rate and the medical evaluation rate were 1.16% and 0.09%, respectively. A third of recalled neonates were low birth weight infants. 5 neonates were proven to have CAH, and its incidence was 1 : 13,478.
The present study demonstrates the feasibility of a neonatal screening for CAH and indicates that the frequency of CAH may be greater than previously reported by case assessment method in Japan.抄録全体を表示PDF形式でダウンロード (1203K) -
第1報 PSL連日投与期のPSL薬物動態五島 英一, 安田 圭吾, 不破 義之, 足立 佳代子, 皆森 良明, 村瀬 寛, 村山 正憲, 山北 宜由, 三浦 清1986 年 62 巻 6 号 p. 697-712
発行日: 1986/06/20
公開日: 2012/09/24
ジャーナル フリーWe studied the pharmacokinetics of prednisolone (PSL) in eight patients (two each with subacute thyroiditis, systemic lupus erythematosus, and nephrotic syndrome : and one each of Crohn's disease and aortitis syndrome) before and during the daily treatment with PSL (duration of 0.5-4.0 months with the mean of 1.9 months; total amount of 0.3-8.0g with the mean of 2.8g).
PSL was measured by radioimmunoassay. Cmax, Tmax and AUCp.o. were calculated on the single oral administration of 40mg PSL, and T1/2β, Vd and MCR were calculated when 25.6mg of PSL sodium succinate (equivalent to 20mg of PSL) was injected intra-venously. Bioavailability was calculated by the ratio of AUCp.o. × PSL i.v. dose to AUCi.v. × PSL p.o. dose. With the oral administration, there was no difference in Cmax, Tmax and AUCp.o. between before and during the treatment, respectively. With the intravenous PSL administration, significant increase of AUCi.v. (p<0.01), significant decrease of MCR (p<0.01), significant elongation of T1/2β (p<0.05), and significant decrease of the bioavailability (p<0.001) were found in the PSL treatment period compared with before the treatment, but no significance was found in Vd between, before, and during the treatment.
There was no difference in these changes in parameters among the diseases. Nor were any correlations found between the changes in these parameters of T1/2β, MCR or bioavailability and the duration or the total amount of PSL administered, respectively.
These results indicate that the decreased MCR, elongated T1/23 and the decreased bioavailability of PSL were brought about by daily administration of PSL, regardless of the kind of diseases, or the total amount or the duration of PSL administration.抄録全体を表示PDF形式でダウンロード (1655K) -
高橋 正樹, 三浦 幸雄, 佐野 直樹, 木村 忍, 鳥谷部 俊一, 石塚 由紀, 大橋 弘文, 野城 孝夫, 菅原 隆, 渡辺 裕志, 吉 ...1986 年 62 巻 6 号 p. 713-723
発行日: 1986/06/20
公開日: 2012/09/24
ジャーナル フリーThe concentrations of unconjugated plasma dopamine (PDA) were studied in patients with various types of hypertension. Catecholamines were extracted from plasma specimens (1.0-3.0ml) through an Amberlite CG50 (Li+-form) microcolumn and eluted by a magnesium sulfate-ethanol solution. The elute was then desalinated and deproteinized by the ethanol-treated precipition procedure and dried in a vacuum oven at 25°C. A fraction of catecholamines was assayed with the modified procedures of the COMT-mediated radio-enzymatic method. This assay system was sensitive enough to permit an accurate measurement of PDA as low as 6.0pg per ml of plasma without any detectable contamination of the conjugated dopamine.
The resting levels of PDA were 10.1 ± 1.0pg/ml (mean ± SEM), 9.5 ± 1.0 and 13.7 ± 0.6 in patients with borderline hypertension (BH, n=25), essential hypertension (EH, n=22) and renovascular hypertension (RVH, n=8), respectively. The values in EH patients were significantly smaller than those in age-matched normal controls (13.0 ± 1.4, n=14, p<0.05). Remarkably increased PDA values were observed in patients with pheochromocytoma (76.5 ± 25.4, n=9, p<0.01). Significantly raised PDA values were also found in patients with primary aldosteronism (PA, 27.8 ± 9.0, n=6, p<0.05), while their plasma norepinephrine levels (PNE, 169 ± 39pg/ml) tended to be lower than those of normal controls (206 ± 20), showing an apparent dissociation between the values of PDA and PNE.
Upright posture for 15 minutes induced a significant rise in PDA (p<0.05) in all subjects except PA patients. The postural changes of PDA, however, were invariably smaller than those of PNE (p<0.05).
The resting values of PDA in normal, BH and EH patients showed a significant negative correlation with their mean arterial pressures (r=-0.301, n=61, p<0.05) and a positive correlation with those of PNE (r= 0.381, p<0.01). There was no correlation between PDA and age in any group studied.
These findings indicate that PDA might not be only a precursor fraction of neurotransmitters released from the sympathetic nervous system but could also represent a physiological function of the dopaminergic regulatory system. The varied but distinctive features of PDA status in various types of hypertension suggest the possibility that the peripheral dopaminergic mechanisms play an inherent role in the pathogenesis of hypertension.抄録全体を表示PDF形式でダウンロード (987K) -
日野 恵, 山本 逸雄, 滋野 長平, 青木 純, 鳥塚 莞爾, 岩元 則幸, 山崎 悟, 福田 豊史, 近藤 守寛, 山本 則之, 小野 ...1986 年 62 巻 6 号 p. 724-736
発行日: 1986/06/20
公開日: 2012/09/24
ジャーナル フリーThe widespread clinical use of hemodialysis has prolonged the survival of a vast number of uremic patients, but it has also yielded some problems including renal osteodystrophy. Recently, it has become well known that the clinical use of active vitamin D metabolites is effective in many patients with renal osteodystrophy. However, there are many patients with bone diseases resistant to such treatment. Several lines of evidences implicate aluminum as one of the causal factors in the production of such diseases. We recently found 20 patients with bone diseases associated with the deposition of aluminum in front of active calcification in the bone.
All of them were undergoing maintenance hemodialysis with softened water thrice weekly and taking aluminum containing antacids and 1α- (OH) D3. The age of the patients ranged between 30 y.o. and 62 y.o. (46.5 ± 9.0, mean ± s.d.). All of them had severe bone pain and 8 of them had bone fractures. Bone X-ray, bone scintigraphy, serum Ca, P, ALP, serum aluminum and bone histology were examined.
Based on the bone histology, they were classified into four types; inactive type (9), osteomalacia type (6), mild type (4) and mixed type (1). There were no significant differences among each group concerning serum values of Ca, P and aluminum. Serum value of ALP tended to be high in the osteomalacia type, and that of c-PTH was significantly low in the inactive type compared with the other types.
Our finding suggest that aluminum associated bone disease is not so rare in Japan and show that the diagnosis of this disease should be made histologically and that clinical and blood chemical features are not reliable for the diagnosis of aluminum associated bone disease in hemodialysis patients.抄録全体を表示PDF形式でダウンロード (3969K) -
湯浅 久子, 今井 強一, 深堀 能立, 山中 英寿1986 年 62 巻 6 号 p. 737-744
発行日: 1986/06/20
公開日: 2012/09/24
ジャーナル フリーIn the present study, size exclusion HPLC was used to analyse the properties of Estramustine-binding protein (EMBP) in the cytosol of human benign prostatic hypertrophy (BPH). The typical size exclusion HPLC separation profile of 3H-Estramustine-labelled cytosol of BPH showed four radioactive peaks that corresponded to the V0, 250K, 68K and 45K protein regions. The specific binding protein for Estramustine is contained mainly in the 250K protein region and in part in the V0 region. In the presence of sodium molybdate, the specific Estramustine binding to a 250K protein was increased to a level which was about 2.5 times as much as the value in the absence of sodium molybdate. The specific Estramustine binding to a 250K protein under the condition of no DCC treatment and the addition of sodium molybdate was 600% of the value obtained under the condition of DCC treatment and no addition of sodium molybdate. These results suggested that sodium molybdate stabilized the specific Estramustine-binding activity to a 250K protein and that specific Estramustine binding to a 250K protein seemed to be weaker than the binding of androgen to androgen receptor.抄録全体を表示PDF形式でダウンロード (679K) -
井上 哲朗, 松岡 良, 森 宏之, 木川 源則1986 年 62 巻 6 号 p. 745-753
発行日: 1986/06/20
公開日: 2012/09/24
ジャーナル フリーThe LH RH agonist Buserelin was continuously adminstered through the nose over an extended period to 5 patients with endometriosis at daily doses ranging between 300μg and 1,200μg. The clinical findings and endocrinological dynamics, with emphasis on PRL secretion function, were investigated and the findings below were obtained.
1. The clinical findings showed Buserelin to be effective against endometriosis.
2. The administration of Buserelin markedly inhibited the secretion of LH and FSH under LH-RH loading.
3. The administration of Buserelin markedly inhibited the secretion of PRL and the degree of inhibition appeared to be dependent on the dose and duration of Buserelin administration.
4. No correlation between E2 and PRL was observed during Buserelin administration.
5. The findings suggest that Buserelin inhibits PRL secretion by direct CNS activity, not indirectly through inhibition of E2 production.抄録全体を表示PDF形式でダウンロード (671K)
- |<
- <
- 1
- >
- >|